What Happened?
New Haven, CT-based BioXcel Therapeutics Appointed Joseph Henderson as Director, Financial Reporting and Technical Accounting
About the Company
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
About the Person
Joseph Henderson is Director, Financial Reporting and Technical Accounting at BioXcel Therapeutics. Previously, Joseph held various senior HR leadership roles in the industry.
Info Source
News
Short Profile